Alembic Pharmaceuticals’ State of the Art Anti-Cancer Manufacturing Facility at Panelav, Halol was inaugurated by the Hon. Chief Minister of Gujarat, Shri Vijaybhai Rupani, in the presence of various dignitaries. Prominent attendees were, Shri Jaydrathsinhji Parmar, Minister of State, Road & Building, Higher and Technical Education, Shri Rajendra Trivedi, Minister of State, Sports, Youth Cultural activities (Independent Charge), Pilgrimage Development.
Speaking on the occasion, Mr Chirayu Amin, CEO and Chairman, Alembic Group of Companies highlighted Alembic Group’s contribution to Gujarat over the last 110 years. He informed the august gathering, of over 1000 guests and employees that the plant, created at an investment of Rs 300 crores, has an initial manufacturing capacity of 60 million tablets / capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates.
With this oncology manufacturing facility being inaugurated, Alembic will make an entry in the growing global oncology segment and will commence exporting, oncology products to US, Middle East, North Africa, Australia and South Africa.
This manufacturing facility is designed with Containment Control Automated Standards & major equipment were imported like BOSCH from Germany, GEA from Belgium, Alexanderwerk from UK, ICOS from Italy, Tofflon from China. He proudly announced that the factory complied with all major Regulatory Standards.
The Chief Minister also inaugurated a Water RO Plant, set up by the Alembic CSR Foundation for the village of Tajpura, near Panelav. He visited the Rural Development Society being run by Alembic Group for last many decades for the overall development of the cluster of villages in and around their manufacturing facilities. In his address to all present, the Chief Minister lauded the efforts of Alembic Group in the development of Gujarat and praised their philanthropic work.
The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India.
The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.
The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.
With an emphasis on innovation and technology, the company has established a state-of-the-art research facility – Alembic Research Centre (ARC)-including formulation research, and a 150-bed bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in an ultra-modern R&D center at Hyderabad. APL is one of the leading players in the industry to have invested about 11% of its turnover in R&D.
As a growth strategy, the company has aggressively started investing in the international generics market with successful ANDA and DMF filings.
APL has also filings across Canada, Europe, Australia, South Africa & Brazil. Alembic has a total of 60 ANDA approvals (52 final approvals and 8 tentative approvals) from USFDA. The company aims to explore opportunities in the therapeutic areas such as Dermatology, Oncology, and Injectable Formulations. APL also has also co-promoted a company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.
As a growth strategy, the company has aggressively started investing in the international generics market with successful ANDA and DMF filings.
APL has also filings across Canada, Europe, Australia, South Africa & Brazil. Alembic has a total of 60 ANDA approvals (52 final approvals and 8 tentative approvals) from USFDA. The company aims to explore opportunities in the therapeutic areas such as Dermatology, Oncology, and Injectable Formulations. APL also has also co-promoted a company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.
